Results 121 to 130 of about 5,019 (231)

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. [PDF]

Adv Sci (Weinh)
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV.   +16 more
europepmc   +1 more source

Epitope‐Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi‐Epitope Bispecific Antibody Framework

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A multi‐epitope digital surface‐enhanced Raman spectroscopy framework enables epitope‐resolved immunoprofiling by integrating bispecific antibody fragments with spectrally encoded nanotags. This approach decouples binding events into independent digital channels, allowing structure‐aware antigen analysis.
Jing Wang, Quan Zhou, Kym Lowry, Christopher B. Howard, Matt Trau   +4 more
wiley   +1 more source

Erratum: A KRAS^G12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [PDF]

Mol Ther Oncol
Huynh N, Thi Nguyen TM, Bui NT, Nguyen HN, Nguyen CT.   +4 more
europepmc   +1 more source

Closing the Translational Gap: Closed‐Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics

Cancer Medicine, Volume 15, Issue 8, August 2026.
Artificial intelligence accelerates cancer therapeutic development through an iterative, closed‐loop pipeline: from AI‐driven target and drug discovery, through automated synthesis and screening, to experimental validation in in vivo tumor models, culminating in clinical translation guided by patient data.
Tuğba Ören Varol, Mehmet Varol
wiley   +1 more source

Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. [PDF]

Int J Mol Sci
Saha N, Lee SG, de Stanchina E, Mendoza RP, Veach DR, Nikolov DB.   +5 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 452-464, August 2026.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ITGA5/integrin α5β1 promotes PDAC progression by integrating fibronectin‐dependent adhesion, hypoxia‐associated ECM remodelling, pancreatic stellate cell/cancer‐associated fibroblast activation, desmoplasia and tumour‒stroma crosstalk. These processes contribute to impaired drug delivery and therapeutic resistance.
Chenzhe Ma, Yingying Wang, Yumin Li
wiley   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source